At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
RGLS8429 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of RGLS8429
In Brief
A Phase 1 clinical trial evaluating RGLS8429 and Placebo volume-matching RGLS8429 dose for Healthy Volunteers. Completed, enrolled 32 participants across 1 site.
Detailed Summary
Primary Objective • To assess the safety and tolerability of single ascending doses of RGLS8429 Secondary Objectives * To identify dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) of a single SC dose of RGLS8429 * To characterize the pharmacokinetic (PK) properties of RGLS8429
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartJun 2022
First PostedJun 2022
Primary CompletionSep 2022
TodayJul 2026
First PostedJun 23, 2022
Enrollment StartJun 10, 2022
Primary CompletionSep 8, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.0 years ago
Interventions
RGLS8429drug
solution for subcutaneous injection
Placebo volume-matching RGLS8429 dosedrug
solution for subcutaneous injection